Clinical Data Viridian tumbles on positive data for key eye drug prospect BioPharma DiveThe data did not meet investor expectations, and could bring fierce investor debate on commercial feasibility, according to an analyst.Clinical DataOphthalmologyRead full story pharminent March 31, 2026 (Last updated: March 31, 2026) BioPharma Dive The data did not meet investor expectations, and could bring fierce investor debate on commercial feasibility, according to an analyst. Clinical DataOphthalmologyRead full story Post navigation Previous: PepGen Loses Half of Share Price on Mixed Data in Rare Muscle-Wasting DiseaseNext: Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026